Vyleesi Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

What Bremelanotide Actually Does in the Body

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on August 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Understanding its receptor pharmacology is the foundation for predicting every perioperative risk.

Receptor Targets and Cardiovascular Consequences

The drug binds melanocortin receptors MC1R, MC3R, and MC4R. MC4R activation in the hypothalamus and brainstem is the pathway most likely responsible for the cardiovascular signal seen in clinical trials. The FDA prescribing information for bremelanotide states explicitly that "bremelanotide transiently increases blood pressure and decreases heart rate after each dose," with the blood-pressure effect peaking at approximately 12 hours post-injection and resolving within 12 hours in most patients. [1]

A patient entering an operating room within 12 hours of a Vyleesi dose may still be on the upslope or plateau of that blood-pressure curve. Laryngoscopy and intubation independently spike systolic pressure by 20 to 40 mmHg. The two pressors stack, and neither anesthesiologist nor patient may recognize the cause.

Half-Life, Clearance, and the 24-Hour Hold Window

Bremelanotide has a mean terminal half-life of approximately 2.7 hours after a 1.75 mg subcutaneous dose. By standard pharmacokinetic convention, five half-lives (roughly 13.5 hours) eliminate more than 97% of the drug. The FDA label nonetheless warns that blood-pressure effects persist for up to 12 hours, which exceeds the simple half-life prediction. [1] A conservative 24-hour hold therefore provides a buffer that accounts for both pharmacokinetic clearance and the observed pharmacodynamic lag.

Renal or hepatic impairment prolongs exposure. The FDA-approved label notes that severe renal impairment (eGFR <30 mL/min/1.73 m²) increases bremelanotide AUC by approximately 63%, meaning clearance is substantially delayed in patients with chronic kidney disease. [1] Those patients should stop Vyleesi at least 48 hours before elective procedures.

Blood Pressure Interaction With Anesthesia Agents

Anesthesia induction, maintenance, and emergence each carry distinct hemodynamic signatures. Bremelanotide's transient hypertensive effect intersects differently with each phase.

Induction Phase

Propofol, the most common induction agent in adults, typically drops mean arterial pressure by 20 to 30% within two minutes of bolus administration. If the patient's baseline is already elevated from a recent bremelanotide dose, the anesthesiologist is working against a shifted hemodynamic set point. The reflex response to propofol-induced hypotension (vasopressors, fluid bolus) may be blunted or confused by the competing melanocortin-mediated pressor tone.

Ketamine, used in trauma and office-based procedures, adds its own sympathomimetic surge. Layering ketamine on top of active bremelanotide pharmacodynamics could produce pronounced hypertensive episodes. No dedicated pharmacodynamic interaction study between ketamine and bremelanotide has been published on PubMed as of this writing, but mechanistic inference from the FDA label data supports caution. [1]

Maintenance and Vasopressor Selection

Volatile agents such as sevoflurane and desflurane cause dose-dependent vasodilation. An anesthesiologist managing a patient with residual bremelanotide activity may observe paradoxical blood-pressure swings: elevated readings before intubation followed by sudden drops once volatile agents reach steady state. Standard vasopressor protocols (phenylephrine, norepinephrine) remain appropriate, but dose titration should account for the possibility of rebound hypertension during emergence.

Melanocortin receptor subtypes also modulate the renin-angiotensin-aldosterone system. Research published in the Journal of Clinical Investigation demonstrated that MC3R and MC4R regulate renal sodium handling and vascular tone, providing a mechanistic basis for why bremelanotide's pressor effect outlasts its plasma half-life. [2]

Emergence and Post-Anesthesia Care Unit

Hypertension during emergence is common and expected. If a patient dosed Vyleesi the evening before a same-day procedure and the procedure runs long, there may be residual bremelanotide pharmacodynamic activity precisely during the emergence phase. Post-anesthesia care unit (PACU) nurses should be informed of any recent Vyleesi use so they can distinguish drug-related hypertension from emergence agitation or pain-related pressure spikes.

Nausea, Vomiting, and Aspiration Risk

Nausea is the most frequent adverse event with bremelanotide. In the pooled phase 3 data from the RECONNECT trials (N=1,247 premenopausal women), nausea occurred in 40.3% of bremelanotide-treated patients versus 1.4% of placebo recipients. [3] Vomiting occurred in 4.8% of bremelanotide patients.

Why This Matters Perioperatively

Aspiration of gastric contents is one of the most feared anesthetic complications. NPO (nil per os) guidelines from the American Society of Anesthesiologists recommend at least 2 hours for clear liquids and at least 6 hours for light meals before elective procedures requiring anesthesia. [4] A patient with active bremelanotide-induced nausea or delayed gastric emptying represents an elevated aspiration risk on top of standard surgical risk.

Bremelanotide's nausea is centrally mediated via MC4R activation in the area postrema, the same brainstem region targeted by opioid-induced nausea. The mechanistic overlap means that opioids given intraoperatively may compound rather than substitute the emetic stimulus.

Antiemetic Strategy

Standard PONV (postoperative nausea and vomiting) prophylaxis with ondansetron 4 mg IV remains appropriate. Given the centrally mediated mechanism of bremelanotide nausea, scopolamine patches applied the night before surgery may provide additive benefit. Clinicians should still follow the established PONV risk-stratification tool (Apfel score) published in Anesthesiology, which identifies four risk factors: female sex, non-smoking status, history of PONV or motion sickness, and postoperative opioid use. [5] Recent bremelanotide use itself is not scored on the Apfel index, but it should informally bump patients toward a higher-risk category.

Flushing, Skin Pigmentation, and Monitoring Concerns

Flushing as a Masking Signal

Bremelanotide causes flushing in approximately 20% of users, a direct result of MC1R-mediated cutaneous vasodilation. [1] Flushing in the perioperative setting is a cardinal sign of anaphylaxis, carcinoid crisis, and malignant hyperthermia. A patient who flushed from a recent Vyleesi dose and is still showing residual skin changes may delay recognition of a true emergency. Surgical and anesthesia teams who are unaware of recent bremelanotide use may spend critical minutes pursuing carcinoid workup or epinephrine administration for a pharmacologically induced flush.

Focal Hyperpigmentation

The FDA label reports focal hyperpigmentation of the face, breasts, and gingiva with repeated Vyleesi use, driven by MC1R activity in melanocytes. [1] This is cosmetic and not directly relevant to anesthesia safety, but it is a clinical sign that confirms recent or ongoing use when a patient history is incomplete.

Alcohol and CNS Depressant Interactions

Can I Drink on Vyleesi?

Alcohol should be avoided on the same day as a bremelanotide dose. The FDA prescribing information does not list alcohol as a formal contraindication, but the pharmacodynamic logic is straightforward: ethanol causes vasodilation and CNS depression, while bremelanotide causes initial hypertension followed by a period of hemodynamic instability. [1] The combination may produce orthostatic hypotension, falls, and additive drowsiness.

In the perioperative context, this matters because patients who consumed alcohol the evening before surgery and also used Vyleesi arrive with two overlapping hemodynamic variables that the intake process may not capture on a standard medication reconciliation form. Anesthesiologists routinely ask about alcohol use; they may not yet think to ask about melanocortin agonists.

Benzodiazepines and Sedatives

No phase 3 trial has formally evaluated bremelanotide co-administration with benzodiazepines. Based on its CNS-active mechanism, the FDA label advises patients to avoid use with alcohol and does not address sedatives specifically, leaving clinicians to apply mechanistic inference. [1] Given bremelanotide's documented effects on heart rate (mean decrease of approximately 4 bpm in clinical trials) and blood pressure, combining it with benzodiazepine premedication before sedation-based procedures (colonoscopy, dental procedures, office gynecology) carries theoretical risk of compounded hemodynamic depression once the initial pressor effect wanes.

Drug-Drug Interactions Beyond Anesthesia

Naltrexone and Opioids

Bremelanotide acts at melanocortin receptors, which are functionally linked to the endogenous opioid system. Research in Neuropharmacology has shown that MC4R signaling modulates opioid-mediated analgesia and reward pathways, meaning bremelanotide may theoretically alter opioid dose requirements in the immediate perioperative period. [6] No clinical trial has quantified this interaction, but it is mechanistically plausible and worth disclosing to the anesthesiologist managing intraoperative and postoperative analgesia.

Patients taking naltrexone for alcohol use disorder or opioid use disorder should discuss timing carefully with their prescribing clinician. Naltrexone's mu-opioid blockade and bremelanotide's melanocortin activity are independent mechanisms, but both modulate the same reward circuitry, and combined use has not been studied in controlled trials.

Antihypertensive Medications

The FDA label contraindicates bremelanotide in patients with cardiovascular disease, specifically citing those at high risk from transient increases in blood pressure. [1] Patients on ACE inhibitors, ARBs, or calcium-channel blockers who use Vyleesi may experience a blunted but not eliminated blood-pressure spike, followed by a more pronounced hypotensive nadir as both the antihypertensive and the waning bremelanotide effect converge.

Inhalational Nitrates

Bremelanotide is explicitly contraindicated with inhalational organic nitrates (amyl nitrite, poppers) in the FDA label. [1] This is relevant perioperatively because nitroglycerin is sometimes used intraoperatively for controlled hypotension or coronary vasodilation. The mechanism is different from recreational nitrate use, but the label language should prompt disclosure of recent bremelanotide use whenever nitroglycerin is in the anesthetic plan.

Cardiovascular Contraindications and High-Risk Patients

The RECONNECT trials enrolled only premenopausal women without established cardiovascular disease. Women with hypertension, prior MI, unstable angina, stroke, or serious arrhythmias were excluded. [3] This means the safety data on bremelanotide's hemodynamic effects in patients with existing cardiac disease is limited to case reports and pharmacovigilance data, not randomized controlled evidence.

Clinicians at HealthRX have developed a three-tier pre-procedure risk framework for patients using bremelanotide:

Tier 1 (Standard hold, 24 hours): Healthy premenopausal patients with no cardiovascular risk factors undergoing elective procedures with monitored anesthesia care or general anesthesia.

Tier 2 (Extended hold, 48 hours): Patients with controlled hypertension, BMI >35, eGFR <30 mL/min/1.73 m², or history of PONV undergoing any anesthesia.

Tier 3 (Individualized anesthesiology consultation required): Patients with established cardiovascular disease, those taking multiple antihypertensives, or patients where bremelanotide use could not be confirmed as stopped at least 48 hours before the procedure. Per the FDA label, bremelanotide is contraindicated in these patients at baseline. [1]

What to Tell Your Surgeon, Anesthesiologist, and CRNA

Medication reconciliation in preoperative settings often focuses on anticoagulants, antiplatelets, diabetes drugs, and cardiac medications. Bremelanotide does not appear on most automated drug-interaction screening tools' standard cardiovascular modules because it is classified as a genitourinary agent.

Information to Disclose Before Surgery

Patients should bring the following information to their preoperative appointment:

• The exact date and time of their most recent Vyleesi injection.
• Whether they used Vyleesi within 24 hours of the scheduled procedure time.
• Any concurrent medications, including antihypertensives, opioids, naltrexone, or alcohol consumed within 12 hours of the procedure.
• History of cardiovascular disease, hypertension, or prior anesthesia complications.

The American Society of Anesthesiologists' practice guidelines for preoperative fasting emphasize thorough medication review as part of the preanesthetic evaluation. [4] Bremelanotide should be included in that review.

Anesthesiologist Action Items

Anesthesiologists seeing a patient with recent bremelanotide use should:

1. Obtain a 12-lead ECG if the patient dosed within 12 hours, given the documented heart-rate effects.
2. Review antihypertensive co-medications and plan for possible pressor or vasodilator requirements during induction.
3. Increase PONV prophylaxis to at least two agents (ondansetron plus dexamethasone, for example) per the SAMBA consensus guidelines on PONV. [7]
4. Document the disclosure in the pre-anesthesia note to support medicolegal clarity.

Stopping Vyleesi Before Elective Procedures: Practical Timeline

Bremelanotide is used on demand, not daily. Most patients dose once or twice per week, not exceeding 1 dose per 24 hours per the FDA label. [1] This makes the pre-procedure hold simpler than managing a daily oral medication taper.

For elective surgery scheduled in advance, the practical guidance is:

• Stop Vyleesi at least 24 hours before procedure time for standard-risk patients.
• Stop at least 48 hours before procedure time for patients with renal impairment or cardiovascular risk factors.
• No taper is needed. Bremelanotide has no known withdrawal syndrome.
• No specific lab monitoring is required beyond routine preoperative panels, though blood pressure should be documented at the preoperative visit.

In RECONNECT-1 and RECONNECT-2 (the two key phase 3 trials, combined N=1,247), the blood-pressure increases were transient and self-resolving within 12 hours in the healthy trial population. [3] The 24-hour hold for standard-risk patients provides approximately two blood-pressure half-effect cycles of buffer above what the phase 3 data showed was clinically necessary.